Anika Appoints Chief Commercial Officer
This article was originally published in Scrip
Anika Therapeutics Inc., a medicines company, has appointed Richard Hague chief commercial officer. Prior to this, Hague was vice-president of sales and marketing for TEI Medical and previously he was vice-president of sales, marketing and commercial operations at Sanofi Biosurgery. He also held leadership positions at Genzyme Biosurgery, including senior director and head of US sales and northeast regional sales director.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.